Johnson & Johnson

Johnson & Johnson Q1 2026 earnings due before market open. Pharma division expected to remain dominant revenue contributor with medtech showing procedure volume recovery. Immunology franchise under scrutiny as biosimilar competition intensifies. Darzalex and specialty drugs driving incremental growth.